Peter Bossuyt
Appearances
- DateMay 20, 2024Improved clinical outcomes and normalization of objective markers of inflammation are important treatment targets per STRIDE-II consensus for patients (pts) with Crohn’s disease (CD)…
Presenter
Icahn School of Medicine, Mount Sinai - DateMay 20, 2024BACKGROUND: Disease clearance in ulcerative colitis (UC) is defined as concurrent achievement of clinical, endoscopic, and histologic remission…
Presenter
Western UniversitySpeakers
Icahn School of Medicine at Mount SinaiKatholieke Universiteit Leuven Universitaire Ziekenhuizen LeuvenWestern University - DateMay 21, 2024BACKGROUND: The primary objective of the VIVID-1 trial (NCT03926130) was to demonstrate efficacy and safety of mirikizumab (miri), a p19-directed anti-IL-23 antibody, compared to placebo (PBO) in patients (pts) with moderate-to-severe Crohn’s disease…
Presenter
Speakers
Mayo ClinicCharité - Universitätsmedizin BerlinWestern University
